Reviva pharmaceuticals announces first patients dosed in pivotal phase 3 study and long-term safety trial evaluating brilaroxazine for the treatment of schizophrenia

- recover is a phase 3, randomized, double-blind study with registrational intent -

RVPH Ratings Summary

RVPH Quant Ranking